"Therapeutic Equivalency" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
| Descriptor ID |
D013810
|
| MeSH Number(s) |
G03.787.559 G07.690.725.898
|
| Concept/Terms |
Therapeutic Equivalency- Therapeutic Equivalency
- Clinical Equivalencies
- Equivalencies, Clinical
- Equivalency, Clinical
- Generic Equivalency
- Equivalencies, Generic
- Equivalency, Generic
- Generic Equivalencies
- Equivalencies, Therapeutic
- Therapeutic Equivalencies
- Equivalency, Therapeutic
- Bioequivalence
- Bioequivalences
- Clinical Equivalency
|
Below are MeSH descriptors whose meaning is more general than "Therapeutic Equivalency".
Below are MeSH descriptors whose meaning is more specific than "Therapeutic Equivalency".
This graph shows the total number of publications written about "Therapeutic Equivalency" by people in this website by year, and whether "Therapeutic Equivalency" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Therapeutic Equivalency" by people in Profiles.
-
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 Mar; 46(3):228-238.
-
Systemic Bioequivalence Is Unlikely to Equal Target Site Bioequivalence for Nanotechnology Oncologic Products. AAPS J. 2019 02 01; 21(2):24.
-
Model-Informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop. Clin Pharmacol Ther. 2018 07; 104(1):27-30.
-
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 03; 81(3):497-503.
-
Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin. Antimicrob Agents Chemother. 1995 Mar; 39(3):668-71.
-
The activation and effects of protein C, an antithrombotic protein, in vivo. Surv Synth Pathol Res. 1984; 3(1):31-7.